MX2023009352A - Metodos para la administracion oftalmica de roflumilast. - Google Patents
Metodos para la administracion oftalmica de roflumilast.Info
- Publication number
- MX2023009352A MX2023009352A MX2023009352A MX2023009352A MX2023009352A MX 2023009352 A MX2023009352 A MX 2023009352A MX 2023009352 A MX2023009352 A MX 2023009352A MX 2023009352 A MX2023009352 A MX 2023009352A MX 2023009352 A MX2023009352 A MX 2023009352A
- Authority
- MX
- Mexico
- Prior art keywords
- eye
- roflumilast
- cornea
- tissues
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148008P | 2021-02-10 | 2021-02-10 | |
| US202163261404P | 2021-09-20 | 2021-09-20 | |
| PCT/US2022/015942 WO2022173923A1 (en) | 2021-02-10 | 2022-02-10 | Methods for ophthalmic delivery of roflumilast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009352A true MX2023009352A (es) | 2023-08-16 |
Family
ID=82704332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009352A MX2023009352A (es) | 2021-02-10 | 2022-02-10 | Metodos para la administracion oftalmica de roflumilast. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12102622B2 (https=) |
| EP (1) | EP4291162A4 (https=) |
| JP (1) | JP2024506384A (https=) |
| AU (1) | AU2022218993A1 (https=) |
| CA (1) | CA3206106A1 (https=) |
| IL (1) | IL304924A (https=) |
| MX (1) | MX2023009352A (https=) |
| WO (1) | WO2022173923A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023049809A1 (en) * | 2021-09-22 | 2023-03-30 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| AU2023341161A1 (en) * | 2022-09-16 | 2025-04-03 | Iolyx Therapeutics, Inc. | High concentration pharmaceutical compositions of roflumilast for ophthalmic delivery |
| WO2025024684A1 (en) * | 2023-07-25 | 2025-01-30 | Iolyx Therapeutics, Inc. | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| SK122199A3 (en) | 1997-03-18 | 2000-12-11 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| US20040242597A1 (en) | 2001-09-19 | 2004-12-02 | Thomas Klein | Combination |
| PT1511516E (pt) | 2002-05-28 | 2009-02-20 | Nycomed Gmbh | Preparação farmacêutica para aplicação tópica |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| AU2005267706B2 (en) | 2004-08-02 | 2011-12-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| US7576069B2 (en) | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| US8663694B2 (en) * | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| DK1906916T3 (da) * | 2005-05-10 | 2009-01-19 | Alcon Inc | Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser |
| BRPI0609227A2 (pt) | 2005-05-10 | 2010-03-09 | Alcon Inc | composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos |
| EP1889620A4 (en) * | 2005-06-09 | 2008-12-10 | Santen Pharmaceutical Co Ltd | EYE DROPS CONTAINING ROFLUMILAST |
| JP2007016024A (ja) * | 2005-06-09 | 2007-01-25 | Santen Pharmaceut Co Ltd | ロフルミラスト点眼液 |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| CA2712017C (en) | 2008-01-18 | 2016-08-09 | Oxagen Limited | Compounds having crth2 antagonist activity |
| RS54413B1 (sr) | 2008-08-22 | 2016-04-28 | Sanofi | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita |
| EP2506878A2 (en) | 2009-12-03 | 2012-10-10 | Lupin Limited | Process for preparing pharmaceutical ophthalmic compositions |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| WO2015132708A1 (en) | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| MX2021003633A (es) | 2018-10-16 | 2021-05-27 | Res Triangle Inst | Dispositivo de depósito biodegradable subcutáneo. |
| EP4061332A4 (en) | 2019-11-24 | 2023-11-29 | Sol-Gel Technologies Ltd. | TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR |
| WO2023049809A1 (en) * | 2021-09-22 | 2023-03-30 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
-
2022
- 2022-02-10 US US17/668,858 patent/US12102622B2/en active Active
- 2022-02-10 MX MX2023009352A patent/MX2023009352A/es unknown
- 2022-02-10 JP JP2023548873A patent/JP2024506384A/ja active Pending
- 2022-02-10 IL IL304924A patent/IL304924A/en unknown
- 2022-02-10 EP EP22753325.4A patent/EP4291162A4/en active Pending
- 2022-02-10 WO PCT/US2022/015942 patent/WO2022173923A1/en not_active Ceased
- 2022-02-10 AU AU2022218993A patent/AU2022218993A1/en active Pending
- 2022-02-10 CA CA3206106A patent/CA3206106A1/en active Pending
-
2024
- 2024-09-26 US US18/897,425 patent/US20250009724A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL304924A (en) | 2023-10-01 |
| WO2022173923A1 (en) | 2022-08-18 |
| US20250009724A1 (en) | 2025-01-09 |
| AU2022218993A1 (en) | 2023-08-03 |
| US20220249451A1 (en) | 2022-08-11 |
| CA3206106A1 (en) | 2022-08-18 |
| US12102622B2 (en) | 2024-10-01 |
| EP4291162A1 (en) | 2023-12-20 |
| JP2024506384A (ja) | 2024-02-13 |
| EP4291162A4 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bengani et al. | Steroid-eluting contact lenses for corneal and intraocular inflammation | |
| MX2023009352A (es) | Metodos para la administracion oftalmica de roflumilast. | |
| AU2011282683B2 (en) | Preservative free brimonidine and timolol solutions | |
| ES2708451T3 (es) | Soluciones de bimatoprost y timolol sin conservantes | |
| KR20140076587A (ko) | 노안, 경도 원시 및 불규칙한 난시의 치료를 위한 조성물 및 방법 | |
| CA3095073A1 (en) | Sap and peptidomimetics for treatment of eye disease | |
| Polat et al. | Combined phacoemulsification and trabectome for treatment of glaucoma | |
| US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
| JP2024506384A5 (https=) | ||
| JP2009515921A (ja) | デクスパンテノール、カルシウムイオン、およびリン酸塩を含まない薬学的組成物、ならびにカルシウムキレート剤および眼科的に適合性の粘性調節剤の使用 | |
| AU2011282679A1 (en) | Preservative free bimatoprost solutions | |
| EP3576799A1 (en) | Ophthalmic compositions for therapeutic and prophylactic uses | |
| JPWO2018074421A1 (ja) | 眼科用剤及び眼科用薬 | |
| CN106943590B (zh) | 一种包含ngf的用于治疗角膜上皮损伤的药物组合物 | |
| WO2019054960A3 (en) | Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging) | |
| CA2453442A1 (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases | |
| Kassumeh et al. | Corneal stromal filler injection as a novel approach to correct presbyopia—An ex vivo pilot study | |
| Park et al. | Spontaneous malignant glaucoma in a longstanding hypotonous eye | |
| US20190099401A1 (en) | Method for protecting corneal endothelial cells from the impact caused by an eye surgery | |
| WO2020138135A1 (ja) | 眼科用組成物 | |
| Galeana | Pharmacologic compound to mitigate presbyopia symptoms | |
| Makhzoum et al. | Secondary angle-closure glaucoma due to posterior synechiae formation following phacovitrectomy | |
| HOXHA | Comparison of latanoprost 0.005% and travoprost 0.004% in patients with primary open angle glaucoma and ocular hypertension | |
| Yoshino et al. | Residual amounts of ophthalmic viscosurgical devices on the corneal endothelium following phacoemulsification | |
| Diniz et al. | Sutura corneana em hidrópsia aguda secundária à ectasia pós LASIK: relato de caso |